<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6174">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026556</url>
  </required_header>
  <id_info>
    <org_study_id>1160-0274</org_study_id>
    <nct_id>NCT03026556</nct_id>
  </id_info>
  <brief_title>The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis</brief_title>
  <official_title>Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban &amp; Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health ResearchTx, LLC (HRTX)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>inVentiv Health Clinical (iVH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense (DOD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of newly initiated
      dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in
      comparison to newly initiated rivaroxaban users and newly initiated apixaban users
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke Overall (hemorrhagic, ischemic, uncertain)</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">47000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran vs. Rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran vs. Apixaban</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        NVAF patients, ≥18 years of age, enrolled within the DoD Military Health System, who have
        newly initiated dabigatran, rivaroxaban, or apixaban. Patients must be treatment naïve
        from OAC use prior to first (index) NOAC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18+ on index date

          -  Patients must have been prescribed either dabigatran, rivaroxaban, or apixaban
             identified by pharmacy claim during the study period. The first dispensing date of
             either study drug will be defined as the index date;

          -  Patients must be treatment naïve from all OAC use prior to the first NOAC
             prescription, during study period.

          -  Patients must have at least 12 months of continuous eligibility prior to the index
             date; -Patients must have at least one diagnosis code of atrial fibrillation, defined
             as ICD- 9-CM diagnosis of 427.31 or ICD-10-CM diagnosis of I48.0, I48.1, I48.2,
             I48.91 on the index date or during the pre-index period.

        Exclusion Criteria:

        Less than 12 months of continuous eligibility in the pre-index period Any claim for OAC
        drug (oral use only) in the pre-index period Diagnosis of hyperthyroidism during the
        pre-index period Having at least one claim for alternative indications; orthopedic
        procedures, VTE (includes DVT &amp;PE) and the index NOAC prescription at the same time, or,
        the alternative indication for anticoagulant occurring within 3 months prior to index date
        in pre-period Having at least one claim with any of the following diagnoses or procedure
        codes in order to exclude patients with &quot;transient&quot; causes of Afib (3 months prior to
        index date in pre-period):

          -  Cardiac surgery

          -  Pericarditis

          -  Myocarditis Having at least one medical claim with any of the following diagnoses or
             procedures codes in order to exclude patients with &quot;valvular&quot; Afib (pre-period):

          -  Mitral stenosis

          -  Mitral stenosis with insufficiency

          -  Mitral valve stenosis and aortic valve stenosis

          -  Mitral valve stenosis and aortic valve insufficiency

          -  Diseases of other endocardial structures

          -  Other and unspecified rheumatic heart diseases

          -  Open heart valvuloplasty without replacement

          -  Open and other replacement of unspecified heart valve

          -  Open and other replacement of aortic valve

          -  Open and other replacement of mitral valve

          -  Open and other replacement of pulmonary valve

          -  Open and other replacement of tricuspid valve

          -  Heart valve replaced by transplant

          -  Heart valve replaced by a mechanical device/prosthesis

          -  Atrioventricular valve repair

          -  Aortic valve valvuloplasty

          -  Unlisted procedure, cardiac surgery

          -  Implantation of catheter-delivered prosthetic aortic heart valve; open thoracic
             approach

          -  Transthoracic cardiac exposure (e.g., sternotomy, thoracotomy, subxiphoid) for
             catheter-delivered aortic valve replacement; without cardiopulmonary bypass

          -  Transthoracic cardiac exposure (e.g., sternotomy, thoracotomy, subxiphoid) for
             catheter-delivered aortic valve replacement; with cardiopulmonary bypass

          -  Replacement, aortic valve, with cardiopulmonary bypass; with prosthetic valve other
             than homograft or stentless valve

          -  Valvuloplasty, mitral valve, with cardiopulmonary bypass

          -  Valvuloplasty, mitral valve, with cardiopulmonary bypass; with prosthetic ring

          -  Valvuloplasty, mitral valve, with cardiopulmonary bypass; radical reconstruction,
             with or without ring

          -  Replacement, mitral valve, with cardiopulmonary bypass

          -  Implantation of catheter-delivered prosthetic pulmonary valve, endovascular approach

          -  Replacement, pulmonary valve

          -  Valvectomy, tricuspid valve, with cardiopulmonary bypass

          -  Valvuloplasty, tricuspid valve; without ring insertion

          -  Valvuloplasty, tricuspid valve; with ring insertion

          -  Replacement, tricuspid valve, with cardiopulmonary bypass
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Amy</last_name>
      <phone>978-525-8314</phone>
      <email>Amy.Ryan@inventivhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>January 18, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
